Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Ortiz, Fernando, Kac, Przemysław R., Brum, Wagner S., Zetterberg, Henrik, Blennow, Kaj, Karikari, Thomas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022272/
https://www.ncbi.nlm.nih.gov/pubmed/36927491
http://dx.doi.org/10.1186/s13024-023-00605-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022272/
https://www.ncbi.nlm.nih.gov/pubmed/36927491
http://dx.doi.org/10.1186/s13024-023-00605-8

Ejemplares similares